NYSE:ZTS - Zoetis Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $229.75
Forecasted Upside: 31.88 %
Number of Analysts: 9
Breakdown:
0 Sell Ratings
2 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$174.21 As of 07/1/2022 05:28 PM ET

▲ +2.32 (1.35%)

1 month | 3 months | 12 months

Get New Zoetis Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ZTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZTS

^$229.75

▲ +31.88% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Zoetis in the last 3 months. The average price target is $229.75, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 31.88% upside from the last price of $174.21.

The Safest Option in Trades!

From Tradewins

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Zoetis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
10 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

1/10/2021

0 strong buy ratings
9 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

4/10/2021

0 strong buy ratings
7 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

7/9/2021

0 strong buy ratings
6 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/7/2021

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/5/2022

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/5/2022

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/4/2022

0 strong buy ratings
7 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/4/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/24/2022	Stifel Nicolaus	Lower Price Target	Buy	$275.00 ➝ $225.00	Low
5/19/2022	The Goldman Sachs Group	Lower Price Target	Buy	$237.00 ➝ $208.00	Low
3/9/2022	Citigroup	Lower Price Target	Neutral	$232.00 ➝ $208.00	High
12/20/2021	Citigroup	Boost Price Target	Neutral	$184.00 ➝ $232.00	Medium
11/18/2021	Morgan Stanley	Initiated Coverage	Overweight	$264.00	High
11/5/2021	Barclays	Boost Price Target	Overweight	$235.00 ➝ $240.00	High
8/25/2021	Argus	Boost Price Target	Buy	$195.00 ➝ $225.00	Low
8/9/2021	Credit Suisse Group	Boost Price Target	Outperform	$206.00 ➝ $230.00	Low
8/6/2021	Barclays	Boost Price Target	Overweight	$208.00 ➝ $235.00	Low
7/16/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
7/13/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$210.00 ➝ $238.00	Low
5/28/2021	Argus	Boost Price Target	Buy	$185.00 ➝ $195.00	Medium
5/12/2021	Citigroup	Boost Price Target		$175.00 ➝ $184.00	Medium
5/7/2021	Raymond James	Boost Price Target	Outperform	$166.00 ➝ $192.00	Medium
5/7/2021	Barclays	Boost Price Target	Overweight	$200.00 ➝ $208.00	Medium
3/8/2021	Raymond James	Upgrade	Market Perform ➝ Outperform	$166.00	Medium
3/8/2021	Bank of America	Upgrade	Neutral ➝ Buy	$180.00	Medium
2/17/2021	Credit Suisse Group	Boost Price Target		$197.00 ➝ $203.00	Low
11/13/2020	Morgan Stanley	Boost Price Target	Equal Weight	$167.00 ➝ $174.00	Low
11/12/2020	Truist Financial	Boost Price Target		$160.00 ➝ $170.00	Low
11/6/2020	Barclays	Boost Price Target	Overweight	$175.00 ➝ $189.00	Medium
9/21/2020	Atlantic Securities	Initiated Coverage	Overweight	$191.00	Low
8/20/2020	Morgan Stanley	Boost Price Target	Neutral ➝ Equal Weight	$125.00 ➝ $167.00	Low
8/14/2020	Edward Jones	Upgrade	Hold ➝ Buy		Low
8/12/2020	G.Research	Downgrade	Buy ➝ Hold		Low
8/12/2020	Gabelli	Downgrade	Buy ➝ Hold		Low
8/10/2020	Truist Financial	Boost Price Target	Neutral ➝ Hold	$112.00 ➝ $160.00	Low
8/10/2020	Citigroup	Boost Price Target	Neutral	$146.00 ➝ $160.00	Low
8/7/2020	Stifel Nicolaus	Boost Price Target	Top Pick ➝ Buy	$155.00 ➝ $170.00	Medium
7/30/2020	Citigroup	Boost Price Target	Neutral	$131.00 ➝ $146.00	Medium
7/20/2020	Bank of America	Boost Price Target	Neutral	$135.00 ➝ $150.00	Medium
6/3/2020	Argus	Reiterated Rating	Buy		Low
5/27/2020	Jefferies Financial Group	Initiated Coverage	Buy	$152.00	High
5/18/2020	Credit Suisse Group	Reiterated Rating	Buy	$147.00	High
5/8/2020	UBS Group	Lower Price Target	Neutral	$146.00 ➝ $126.00	Low
5/8/2020	Citigroup	Lower Price Target	Neutral	$139.00 ➝ $131.00	Low
5/7/2020	Barclays	Boost Price Target	Overweight	$129.00 ➝ $140.00	Medium
4/2/2020	Morgan Stanley	Lower Price Target	Equal Weight	$148.00 ➝ $125.00	High
3/31/2020	G.Research	Upgrade	Hold ➝ Buy		High
2/28/2020	The Goldman Sachs Group	Reiterated Rating	Buy	$162.00	High
2/19/2020	UBS Group	Boost Price Target	Neutral	$126.00 ➝ $146.00	Low
2/14/2020	Morgan Stanley	Boost Price Target	Equal Weight	$136.00 ➝ $148.00	Low
2/14/2020	SunTrust Banks	Reiterated Rating	Hold	$145.00	Low
2/13/2020	Cfra	Upgrade	Buy ➝ Strong-Buy	$147.00 ➝ $160.00	Low
2/12/2020	Bank of America	Reiterated Rating	Hold	$145.00	Medium
1/9/2020	Raymond James	Initiated Coverage	Market Perform		Low
12/5/2019	Bank of America	Reiterated Rating	Hold	$125.00	Low
10/11/2019	Credit Suisse Group	Set Price Target	Buy	$138.00	Low
9/30/2019	Morgan Stanley	Boost Price Target	Hold ➝ Equal Weight	$100.00 ➝ $136.00	Low
9/13/2019	Stifel Nicolaus	Set Price Target	Buy	$140.00	Medium
9/11/2019	Credit Suisse Group	Reiterated Rating	Buy	$130.00	High
9/9/2019	The Goldman Sachs Group	Initiated Coverage	Conviction-Buy	$145.00	Medium
9/4/2019	Argus	Set Price Target	Buy	$140.00	Low
8/13/2019	SunTrust Banks	Boost Price Target	Hold	$120.00 ➝ $130.00	Low
8/7/2019	Craig Hallum	Boost Price Target	Buy	$132.00 ➝ $138.00	Low
8/7/2019	Barclays	Boost Price Target	Overweight	$120.00 ➝ $135.00	Low
7/22/2019	Stifel Nicolaus	Boost Price Target	Buy	$110.00 ➝ $130.00	Medium
7/1/2019	Bank of America	Downgrade	Buy ➝ Neutral	$111.00 ➝ $120.00	Low
6/25/2019	Craig Hallum	Boost Price Target	Buy	$114.00 ➝ $132.00	Low
6/12/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$116.00 ➝ $130.00	Low
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$120.00	Low
5/23/2019	Guggenheim	Initiated Coverage	Buy ➝ Buy	$114.00	Low
5/9/2019	BMO Capital Markets	Boost Price Target	Market Perform	$101.00 ➝ $105.00	Low
5/2/2019	Gabelli	Downgrade	Buy ➝ Hold	$108.00	Low
4/2/2019	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$102.00 ➝ $112.00	Low
3/20/2019	UBS Group	Initiated Coverage	Neutral		Low
3/19/2019	SunTrust Banks	Initiated Coverage	Hold ➝ Hold	$100.00	Low
3/4/2019	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$97.00 ➝ $110.00	Medium
2/25/2019	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$93.00 ➝ $101.00	Low
1/23/2019	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$86.00	Low
11/13/2018	Argus	Set Price Target	Buy	$105.00	Medium
11/12/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Neutral	$93.00	Low
11/11/2018	BMO Capital Markets	Reiterated Rating	Hold		Low
11/2/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$100.00 ➝ $101.00	Low
11/2/2018	Morgan Stanley	Set Price Target	Hold	$100.00	Low
10/17/2018	Cantor Fitzgerald	Reiterated Rating	Overweight	$98.00 ➝ $105.00	Low
10/15/2018	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$100.00	Medium
10/1/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$98.00	Low
8/21/2018	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$95.00	High
8/14/2018	Argus	Boost Price Target	Buy ➝ Buy	$90.00 ➝ $103.00	Low
8/3/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$86.00 ➝ $95.00	Low
8/3/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Hold	$87.00 ➝ $92.00	Low
8/2/2018	BMO Capital Markets	Reiterated Rating	Hold	$82.00	High
8/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$98.00	High
7/30/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$97.00 ➝ $100.00	Low
7/27/2018	Cantor Fitzgerald	Set Price Target	Buy	$98.00	Low
7/13/2018	Jefferies Financial Group	Set Price Target	Buy	$96.00	Medium
6/6/2018	Cantor Fitzgerald	Set Price Target	Buy	$98.00	Low
5/16/2018	BMO Capital Markets	Reiterated Rating	Hold	$80.00	Low
5/16/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$98.00	Low
5/1/2018	Cantor Fitzgerald	Set Price Target	Buy	$90.00	Low
4/25/2018	Craig Hallum	Reiterated Rating	Buy	$87.00 ➝ $94.00	Low
4/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$90.00	Medium
4/19/2018	Hilliard Lyons	Downgrade	Neutral		Low
4/19/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $98.00	Low
4/13/2018	Jefferies Financial Group	Reiterated Rating	Buy	$96.00	Low
4/5/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$83.00 ➝ $89.00	Low
3/19/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$70.00	Low
2/26/2018	Jefferies Financial Group	Set Price Target	Buy	$97.00	Low
2/17/2018	Barclays	Set Price Target	Hold	$77.00	Medium
2/16/2018	Deutsche Bank Aktiengesellschaft	Boost Price Target	Hold ➝ Hold	$76.00 ➝ $78.00	Low
2/16/2018	Piper Jaffray Companies	Set Price Target	Buy	$88.00	Low
2/16/2018	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $86.00	Medium
2/16/2018	Bank of America	Boost Price Target	Buy	$80.00 ➝ $87.00	Medium
2/15/2018	Cantor Fitzgerald	Set Price Target	Buy	$90.00	Medium
2/15/2018	BMO Capital Markets	Set Price Target	Hold	$78.00	Medium
2/15/2018	Cowen	Set Price Target	Buy	$85.00	Medium
1/22/2018	BMO Capital Markets	Set Price Target	Hold	$78.00	Low
1/18/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$86.00	Low
1/16/2018	Jefferies Financial Group	Reiterated Rating	Buy	$89.00	High
1/11/2018	Cantor Fitzgerald	Set Price Target	Buy	$85.00	Low
1/9/2018	BMO Capital Markets	Boost Price Target	Positive ➝ Market Perform	$78.00	Medium
1/8/2018	BMO Capital Markets	Reiterated Rating	Hold		Low
1/4/2018	Citigroup	Upgrade	Neutral ➝ Buy	$85.00	Low
1/2/2018	Craig Hallum	Reiterated Rating	Buy	$77.00 ➝ $85.00	Low
1/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$85.00	Low
12/26/2017	Cantor Fitzgerald	Set Price Target	Buy	$85.00	Low
12/12/2017	Cantor Fitzgerald	Set Price Target	Buy	$80.00	Low
11/29/2017	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$80.00	Low
11/24/2017	UBS Group	Reiterated Rating	Buy ➝ Neutral		N/A
11/17/2017	Cowen	Set Price Target	Buy	$70.00 ➝ $80.00	N/A
11/10/2017	Jefferies Financial Group	Reiterated Rating	Buy		N/A
11/3/2017	BMO Capital Markets	Boost Price Target	Market Perform	$65.00 ➝ $70.00	N/A
11/3/2017	Morgan Stanley	Boost Price Target	Equal Weight	$61.00 ➝ $70.00	N/A
11/2/2017	BMO Capital Markets	Reiterated Rating	Hold	$65.00	N/A
10/31/2017	Cantor Fitzgerald	Set Price Target	Buy	$75.00	N/A
10/25/2017	BMO Capital Markets	Set Price Target	Hold	$65.00	N/A
10/24/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	N/A
10/24/2017	Stifel Nicolaus	Reiterated Rating	Buy	$65.00	N/A
9/26/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low
9/6/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low
9/1/2017	Stifel Nicolaus	Reiterated Rating	Buy	$65.00	Low
8/25/2017	Piper Jaffray Companies	Set Price Target	Buy	$73.00	Low
8/24/2017	Cowen	Set Price Target	Buy	$70.00	Low
8/14/2017	Cantor Fitzgerald	Set Price Target	Buy	$75.00	Low
8/7/2017	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$62.00	Low
7/25/2017	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$65.00	High
7/21/2017	Stifel Nicolaus	Reiterated Rating	Buy	$65.00	Low
7/17/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$62.00 ➝ $65.00	Low
7/17/2017	Cowen	Set Price Target	Buy	$70.00	Low
7/11/2017	Cowen	Set Price Target	Buy	$60.00	Low

(Data available from 7/4/2017 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
27 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

12/6/2021

2 very positive mentions
16 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/5/2022

4 very positive mentions
16 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

2/4/2022

6 very positive mentions
32 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/6/2022

3 very positive mentions
14 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

4/5/2022

2 very positive mentions
6 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

5/5/2022

4 very positive mentions
40 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

6/4/2022

10 very positive mentions
12 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

7/4/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Today's Range

Now: $174.21

$170.50

$174.50

50 Day Range

MA: $167.68

$155.97

$181.31

52 Week Range

Now: $174.21

$154.18

$249.27

Volume

71,713 shs

Average Volume

2,378,639 shs

Market Capitalization

$81.99 billion

P/E Ratio

39.96

Dividend Yield

0.75%

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Zoetis?: The following Wall Street analysts have issued research reports on Zoetis in the last twelve months: Argus, Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Morgan Stanley, Raymond James, Stifel Nicolaus, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ZTS.
What is the current price target for Zoetis?: 0 Wall Street analysts have set twelve-month price targets for Zoetis in the last year. Their average twelve-month price target is $229.75, suggesting a possible upside of 31.9%.
View the latest price targets for ZTS.
What is the current consensus analyst rating for Zoetis?: Zoetis currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZTS will outperform the market and that investors should add to their positions of Zoetis.
View the latest ratings for ZTS.
What other companies compete with Zoetis?: Other companies that are similar to Zoetis include Johnson & Johnson, Eli Lilly and, Pfizer, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Corcept Therapeutics, Pacira BioSciences, Supernus Pharmaceuticals, Nektar Therapeutics and Omeros. Learn More about companies similar to Zoetis.
How do I contact Zoetis' investor relations team?: Zoetis' physical mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company's listed phone number is (973) 822-7000 and its investor relations email address is [email protected] The official website for Zoetis is www.zoetis.com. Learn More about contacing Zoetis investor relations.

A One Stop Shop for Everything Futures Trading

From RJO Futures

Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!

NYSE:ZTS - Zoetis Stock Price Target and Predictions

Analyst Price Target for ZTS

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.70 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Zoetis?

What is the current price target for Zoetis?

What is the current consensus analyst rating for Zoetis?

What other companies compete with Zoetis?

How do I contact Zoetis' investor relations team?